Taipei Exchange approved Ever Supreme IPO Submission for OTC application on Oct 15.

Taipei Exchange approved Ever Supreme IPO Submission for OTC application on Oct 15.

Ever Supreme Bio Technology applied for OTC as technological entity, in which the company mainly executes the new drug development of immune cells and stem cells, and as the CMO of the medical facilities under RGSCTT in Taiwan and manufacture therapeutic drug products needed by the medical facilities.  Ever Supreme is officially taking steps towards capital markets, and expected to have positive and continual development on its researches and the business operations.